Sexual health / melanocortin
PT-141 (Bremelanotide)
FDA-approvedBremelanotide, Vyleesi · Melanocortin receptor agonist
FDA-approved melanocortin agonist for low sexual desire in women.
What it is
A cyclic heptapeptide analog of alpha-MSH, approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; a metabolite of Melanotan II.
How it works
Activates central melanocortin receptors (chiefly MC4R) in the brain to increase sexual desire — a CNS mechanism, not vascular.
Studied for
HSDD in premenopausal women (approved); male libido/ED (off-label).
Regulatory status
FDA-approved (Vyleesi); 'PT-141' from research vendors is unregulated.
Safety
Nausea, flushing, headache, injection-site reactions; can transiently raise blood pressure (avoid in uncontrolled hypertension/CVD); focal hyperpigmentation with repeated use.
What the community reports about PT-141 (Bremelanotide)
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The libido peptide. FDA-approved as Vyleesi for women's HSDD; widely used off-label in men. On-demand dosing, not daily.
- Central libido enhancer — dramatic desire and erection effects in both sexes
- Nausea is common; flushing, clumsiness; some quit over the sides
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.